我们集团组织了 3000 多个全çƒç³»åˆ—会议 æ¯å¹´åœ¨ç¾Žå›½ã€æ¬§æ´²å’Œç¾Žå›½ä¸¾åŠžçš„æ´»åŠ¨äºšæ´²å¾—åˆ° 1000 多个科å¦åä¼šçš„æ”¯æŒ å¹¶å‡ºç‰ˆäº† 700+ å¼€æ”¾èŽ·å–æœŸåˆŠåŒ…å«è¶…过50000å知å人士ã€çŸ¥åç§‘å¦å®¶æ‹…任编委会æˆå‘˜ã€‚
å¼€æ”¾èŽ·å–æœŸåˆŠèŽ·å¾—æ›´å¤šè¯»è€…å’Œå¼•ç”¨
700 ç§æœŸåˆŠ å’Œ 15,000,000 å读者 æ¯ä»½æœŸåˆŠ 获得 25,000 多å读者
Efstathia Kalli, Vlamos Panayiotis
Individualized nutritional treatment with polyphenols has been proposed in the early stages of Alzheimer’s disease. However, it remains unclear at what doses polyphenols and their metabolites enter the brain tissue and whether they can act at sufficient concentrations. The present review provides useful insights into the multiple modes of actions of selected polyphenols as potential therapeutic tools at the pre-clinical stage of Alzheimer’s disease, as well as their ability to cross the blood-brain barrier and their detrimental effects after high dose consumptions. Several studies proposed flavonoids for their potential value in prevention and treatment of neurodegenerative diseases. The scarcity of clinical data though highlights the need for conducting metabolomics studies and well-designed clinical trials. Prolonged clinical trials with bioinformatics tools are needed to fully elucidate both neuroprotective effects and possible risks from polyphenol consumption at concentrated high doses.